The first ever clinical study evaluating combined transcranial direct current stimulation (tDCS) and behaviour therapy could point to a new treatment for depression.
Flow, a medical device company, launched a medication-free treatment for depression comprising a brain stimulation headset and therapy app.
England’s National Health Service reached a deal to pay for U.S. drugmaker Biogen Inc.’s expensive spinal muscle atrophy treatment Spinraza.
The U.S. FDA approved AbbVie’s Mavyret for all six strains of hepatitis C in children ages 12 to 17 years. The drug was approved for adults 18 years or older during 2017.
With a goal of eradicating hepatitis C, NHS England has teamed up Gilead Sciences Inc., Merck & Co. and AbbVie Inc.
